Kazushi Araki

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Enhancer of zeste homolog 1/2 dual inhibitor valemetostat outperforms enhancer of zeste homolog 2-selective inhibitors in reactivating latent HIV-1 reservoirs ex vivo.

Enhancer of zeste homolog 1/2 dual inhibitor valemetostat outperforms enhancer of zeste homolog 2-selective inhibitors in reactivating latent HIV-1 reservoirs ex vivo.

Journal: Frontiers in microbiology

Published: February 22, 2025

EZH1/2 dual inhibitors suppress HTLV-1-infected cell proliferation and hyperimmune response in HTLV-1-associated myelopathy.

EZH1/2 dual inhibitors suppress HTLV-1-infected cell proliferation and hyperimmune response in HTLV-1-associated myelopathy.

Journal: Frontiers in microbiology

Published: February 28, 2023

CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.

CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.

Journal: Cancer science

Published: November 10, 2020

Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.

Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.

Journal: Cell reports

Published: April 01, 2019

Structure-Activity Relationship Studies of 3- or 4-Pyridine Derivatives of DS-6930.

Structure-Activity Relationship Studies of 3- or 4-Pyridine Derivatives of DS-6930.

Journal: ACS medicinal chemistry letters

Published: December 20, 2018

Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.

Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.

Journal: Cancer science

Published: August 09, 2018

Discovery of DS-6930, a potent selective PPARγ modulator. Part I: Lead identification.

Discovery of DS-6930, a potent selective PPARγ modulator. Part I: Lead identification.

Journal: Bioorganic & medicinal chemistry

Published: July 20, 2018

Discovery of DS-6930, a potent selective PPARγ modulator. Part II: Lead optimization.

Discovery of DS-6930, a potent selective PPARγ modulator. Part II: Lead optimization.

Journal: Bioorganic & medicinal chemistry

Published: July 20, 2018

IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.

IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.

Journal: Cancer research

Published: July 30, 2014

Synthesis and biological evaluation of novel (-)-Cercosporamide derivatives as potent selective PPARγ modulators.

Synthesis and biological evaluation of novel (-)-Cercosporamide derivatives as potent selective PPARγ modulators.

Journal: European journal of medicinal chemistry

Published: April 09, 2012

Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPARγ partial agonists.

Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPARγ partial agonists.

Journal: Bioorganic & medicinal chemistry letters

Published: October 29, 2011

Showing 1-11 of 11

Last Updated: 09/26/2026